La cadena de opciones muestra datos clave de las opciones de acciones de Hepion Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Hepion Pharmaceuticals..

Hepion Pharmaceuticals (OTC:HEPA) Bolsa, Cadena de Opciones

Hepion Pharmaceuticals

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Stock Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADTX

ANAB

ANIK

ANNA

AREB

ASBP

CDLX

ELME

FAMI

HEPA

INTC

NOVA

PATH

SGBX

SNES

STGW

YOSH

Intel designa un nuevo CEO y sus acciones suben con fuerza en el premercado. Descubre qué otros valores destacan hoy.

Las acciones de Intel suben más del 10%; 20 acciones que se están moviendo en el premercado

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

HEPION PHARMS INC by Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Inc

DA Davidson analyst Brent Thielman maintains KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) with a Buy and lowers the price target from $72 to $65.

Price Target

Analyst Ratings

DA Davidson Maintains Buy on KBR, Lowers Price Target to $65

DA Davidson analyst Brent Thielman maintains Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) with a Neutral and raises the price target from $305 to $395.

DA Davidson Maintains Neutral on Quanta Services, Raises Price Target to $395

<a href="https://www.bloomberg.com/news/articles/2025-08-01/wal-mart-de-mexico-ceo-ignacio-caride-resigns-abruptly">https://www.bloomberg.com/news/articles/2025-08-01/wal-mart-de-mexico-ceo-ignacio-caride-resigns-abruptly</a>

General

'Wal-Mart de Mexico CEO Ignacio Caride Resigns Abruptly'- Bloomberg

DA Davidson analyst Brent Thielman maintains WillScot Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) with a Buy and lowers the price target from $45 to $40.

DA Davidson Maintains Buy on WillScot Holdings, Lowers Price Target to $40

DA Davidson analyst Gil Luria maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $230 to $265.

AMZN

DA Davidson Maintains Buy on Amazon.com, Raises Price Target to $265

Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) has outperformed the market over the past 10 years by 9.98% on an annualized basis producing an average annual return of 21.54%. Currently, Apple has a market capitalization of $3.04 trillion. 
Buying $100 In AAPL: If an investor had bought $100 of AAPL stock 10 years ago, it would be worth $701.49 today based on a price of $202.50 for AAPL at the time of writing.
<h3>Apple's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754084728_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPL

Here's How Much You Would Have Made Owning Apple Stock In The Last 10 Years

DA Davidson analyst Gil Luria maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Buy and maintains $250 price target.

DA Davidson Maintains Buy on Apple, Maintains $250 Price Target

Dividends

Array Digital Infrastructure Announces Special Dividend Of $23.00  Payable On August 19, 2025

DA Davidson analyst Clark Wright assumes Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Neutral rating and raises Price Target to $28.

Initiation

FIVN

DA Davidson Assumes Five9 at Neutral, Raises Price Target to $28

Offerings

SCNX

Scienture Holdings Files For Mixed Shelf Offering Of Up To $200M

TWC Enterprises (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TWC#TSX">TWC</a>) reported quarterly earnings of $0.88 per share. This is a 576.92 percent increase over earnings of $0.13 per share from the same period last year. The company reported $61.560 million in sales this quarter. This is a 1.00 percent decrease over sales of $62.183 million the same period last year.

Earnings

TSX:TWC

TWC Enterprises Q2 EPS $0.88 Up From $0.13 YoY, Sales $61.560M Down From $62.183M YoY

TTEC

TTEC Holdings CEO Kenneth Tuchman Withdraws Acquisition Proposal; CEO Not To Pursue His Previously Announced Proposal Due To Market Conditions

Buybacks

MELI

MercadoLibre Says Board Authorized Company To Buy Back Its Own Common Stock Up To A Total $4.05M

Stock Split

HCTI

Healthcare Triangle Effects 1-For-249 Reverse Stock Split

Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) has outperformed the market over the past 5 years by 6.69% on an annualized basis producing an average annual return of 20.19%. Currently, Spotify Technology has a market capitalization of $129.05 billion. 
Buying $100 In SPOT: If an investor had bought $100 of SPOT stock 5 years ago, it would be worth $246.49 today based on a price of $627.15 for SPOT at the time of writing.
<h3>Spotify Technology's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754083827_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SPOT

Here's How Much You Would Have Made Owning Spotify Technology Stock In The Last 5 Years

Compass Point analyst Merrill Ross upgrades Independence Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) from Neutral to Buy and raises the price target from $22 to $24.

Upgrades

Compass Point Upgrades Independence Realty Trust to Buy, Raises Price Target to $24

<a href="https://x.com/bradlightcap/status/1951389149149405618?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/bradlightcap/status/1951389149149405618?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

MSFT

OpenAI COO Brad Lightcap Posts On X "we have surpassed 5M paying business users on chatgpt, up from 3M in june.we continue to see growth in every segment, from small startups and SMBs to fortune 500. we are working to make it easier for companies of any size to get to implementation and success quickly.."

Trump Media & Technology Q2 EPS $(0.08) Up From $(0.10) YoY, Sales $883.30K Up From $836.90K YoY

CIBC analyst Hamir Patel maintains Methanex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) with a Outperformer and raises the price target from $42 to $44.

MEOH

CIBC Maintains Outperformer on Methanex, Raises Price Target to $44

CIBC maintains Gildan Activewear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIL#NYSE">GIL</a>) with a Outperformer and raises the price target from $56 to $60.

CIBC Maintains Outperformer on Gildan Activewear, Raises Price Target to $60

Press Releases

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B

Health Care

Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

Hepion Pharmaceuticals Announces $9.0 Million Public Offering

Hepion Pharmaceuticals Announces Reverse Stock Split

Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer

Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

Comments

Hepion Pharmaceuticals

Hepion Pharmaceuticals (HEPA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL